PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
June 7, 2026Diabetes0 citations

LIVERFAST Outperforms FIB-4 in Identifying Advanced Fibrosis in MASLD Patients

1780-P: LIVERFAST Outperforms FIB-4 in Sequential Combination with Vibration Controlled Transient Elastography (VCTE) for Identifying ≥F3 Stage in Patients with MASLD Including Patients with Type 2 Diabetes

View Full Paper
Ask AI
Bookmark
Share

Authors

MDMarie DecraeckerJHJean‐Baptiste HiriartMIMarie Irlès‐Depé

Discussion

Loading...

Member takes

Overview

Retrospective study finds LIVERFASt improves identification of advanced fibrosis in MASLD, indicating better screening in high-risk patients.

Key Points

  • This study aims to compare the effectiveness of LIVERFASt versus FIB-4, each combined with VCTE, in identifying advanced fibrosis in MASLD patients.
  • Included MASLD patients from a tertiary hepatology center assessed with LIVERFASt, FIB-4, VCTE, and liver biopsy within 6 months.
  • Evaluated performance metrics such as sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV).
  • LIVERFASt showed almost twice the sensitivity compared to FIB-4 for ≥F3 fibrosis, especially at high FIB-4 cut-offs.
  • The combination of LIVERFASt and VCTE achieved a higher PPV of 90.4% compared to 76% for FIB-4 and VCTE.
  • Biopsy confirmed LIVERFASt results more frequently than FIB-4 in discordant VCTE cases.

Cite This Study

Decraecker et al. (2026) studied this question.

synapsesocial.com/papers/6a250b8b7def13d035e1b942https://doi.org/10.2337/db26-1780-p
View Full Paper
Ask AI
Bookmark
Share